WORLD-TECHNOLOGY-GAMES
25.7.2024 15:01:31 CEST | Business Wire | Press release
The World Technology Games (WTG), a groundbreaking global competition in innovation, technology and science, announced its inaugural event for Q3 2026. The annual, five-day event will include Competitions, a Festival and a Leadership Summit. The Games will celebrate and elevate advancements across Life, Earth, Data and Industrial Sciences, through unifying themes like sustainability and AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725287146/en/
World Technology Games CEO Alexander Brown and Gabriela Ramos, Assistant Director-General for the Social and Human Sciences of UNESCO, at The UNESCO “Change the Game” Ministerial Sport Conference in Paris on July 23, 2024. (Photo: Business Wire)
“We built the World Technology Games to inspire people around the world to create technological solutions for today’s most formidable challenges,” said Alexander Brown, CEO of the World Technology Games. “Our first-of-its-kind international event will convene brilliant minds from diverse backgrounds to compete, collaborate, and catalyze change at global scale.”
The World Technology Games were showcased by Mr. Brown at the UNESCO “Change the Game” Global Sport Conference as France hosts the 2024 Olympic Games. The WTG underscored its commitment to support key UN Sustainable Development Goals and to UNESCO’s vision of building multilateral collaboration on education, science, culture, communication and information.
The WTG will honor the ambition, competitive spirit and ingenuity that drive today’s greatest technological contributions. An international cohort of scientists, engineers and innovators will unite for two categories of cutting-edge competitions that aim to entertain and empower people through technology, passion and purpose. “Spotlights” are organized in partnership with established leagues, including support from the Indy Autonomous Challenge and the Global Esports Federation. Unique to the Games, “Originals” are characterized by scientific rigor, real-world application and technological acumen, including culinary creativity, sustainable fashion design, robotics and more.
Through the live event and digital content, the WTG targets a global audience of more than 1.6 billion people who consider technology an essential component of their daily lives. With a focus on engaging Gen T – the nearly 700 million individuals globally who are poised to shape the future of technology – the Games will be amplified by a multi-channel approach distributed across social, digital, podcasts, streaming platforms and linear broadcast.
The WTG is led by Alexander Brown. Mr. Brown has a proven track record of building and growing businesses at a global scale including serving as Managing Director of ESPN Asia and ESPN Star Sports, as well as leadership positions with the NBA, Univision and One World Sports. Brown also served as President & CEO of CNBC Asia. Chairman of the Board, Paul J. Foster is CEO & Member of the Board for the Global Esports Federation and focuses on integrating innovative technology with social impact. He brings more than 20 years of experience in the Olympic Movement, an extensive tenure at the International Olympic Committee and global strategic consulting. The WTG is championed by an International Advisory Council of multidisciplinary experts from more than 20 countries who have spearheaded the growth of global companies and organizations across science, technology, diplomacy, entertainment, and finance.
The Games will also feature an immersive festival and thought leadership summit. The World Technology Festival will celebrate the intersection of technology, art and culture through exhibitions, product showcases and workshops. The World Technology Summit will convene industry experts with keynote speeches, debates and expert panels to explore future trends and the transformative potential of technology.
The inaugural host city selection has begun, with cities worldwide encouraged to submit expressions of interest through September 2024. For more information on the World Technology Games please visit: https://worldtechnology.games/.
About the World Technology Games:
The World Technology Games (WTG) is a global, first-of-its-kind competition celebrating human ingenuity in Life, Earth, Data and Industrial sciences. Set to debut in 2026, the annual five-day event will convene scientists, engineers and innovators from around the world for a series of cutting-edge competitions, a festival and a leadership summit that address humanity’s greatest challenges through technology, passion and purpose. Led by an accomplished leadership team of global multidisciplinary experts, the WTG will empower and entertain a worldwide audience by honoring the unheralded, yet brilliant minds behind today’s greatest advancements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725287146/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom